Increasing the chances for platinum-sensitive ovarian cancer patients.

Item

http://www.wikidata.org/entity/Q38160259

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Increasing the chances for platinum-sensitive ovarian cancer patients.

@en

type

Item

label

Increasing the chances for platinum-sensitive ovarian cancer patients.

@en

prefLabel

Increasing the chances for platinum-sensitive ovarian cancer patients.

@en

P1476

Increasing the chances for platinum-sensitive ovarian cancer patients.

@en

P2093

Antonio González

http://www.w3.org/2001/XMLSchema#string

P2860

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment.

Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwe

Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.

Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.

Clinical trials in recurrent ovarian cancer.

Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer.

Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer.

Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.

Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study.

P304

29-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.13.204

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

12 Suppl

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24195528

http://www.w3.org/2001/XMLSchema#string

P921

ovarian cancer